*.- PM184 Phase II Trial Initiated for Advanced Breast Cancer ( February 2016) .*.- Sylentis Obtiene Resultados Positivos en Fase II con SYL1001 para Tratar el Dolor Ocular / Síndrome de Ojo Seco . Fase III es Viable . ( Marzo 2016 ) .
*.- Aplidin® Positive Final Data for Phase III for Multiple Myeloma (Q1 2016) .
*.- Aplidin® Phase Pivotal Trial Initiated for T- Cell Lymphoma . (June . 2016) .
*.- PM1183 Phase III Pivotal Trial Initiated for SCLC (Aug. 2016) .
*.- PM1183 Interim Activity Analysis Phase III in Platinum-Resistant Ovarian Cancer (Aug. 2016) .
*.- Aplidin® Dossier Submitted for Multiple Myeloma (Sept. 2016) .
*.- PM1183 Data for Phase II Metastatic Breast Cancer (Sept. 2016) .
*.- PM1183 Phase III in Platinum-Resistant Ovarian Cancer : Recruitment Completed (Oct. 2016) .
*.- PM1183 Phase I Trial Initiated Japan (Dec - 2016) .